Published in Hepatology on August 24, 2011
Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med (2013) 2.02
Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response. Hepatology (2012) 1.43
Emerging concepts in immunity to hepatitis C virus infection. J Clin Invest (2013) 1.12
Natural killer cells: multifaceted players with key roles in hepatitis C immunity. Immunol Rev (2013) 0.95
Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat. J Virol (2015) 0.90
Natural killer KIR3DS1 is closely associated with HCV viral clearance and sustained virological response in HIV/HCV patients. PLoS One (2013) 0.87
The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent. Int J Mol Sci (2014) 0.85
Natural killer cell functional dichotomy: a feature of chronic viral hepatitis? Front Immunol (2012) 0.85
The natural killer cell response to HCV infection. Immune Netw (2013) 0.82
Alterations in NK cell phenotype in relation to liver steatosis in children with chronic hepatitis C. Inflammation (2013) 0.79
Synergistic inhibition of natural killer cells by the nonsignaling molecule CD94. Proc Natl Acad Sci U S A (2013) 0.79
Individualization of chronic hepatitis C treatment according to the host characteristics. World J Gastroenterol (2014) 0.78
Frequency and role of NKp46 and NKG2A in hepatitis B virus infection. PLoS One (2017) 0.78
Immunopathogenesis of Hepatitis C Virus Infection. Gastroenterol Clin North Am (2015) 0.77
Natural killer cell function and dysfunction in hepatitis C virus infection. Biomed Res Int (2014) 0.77
TCRγδ(+)CD4(-)CD8(-) T cells suppress the CD8(+) T-cell response to hepatitis B virus peptides, and are associated with viral control in chronic hepatitis B. PLoS One (2014) 0.76
Investigation of Pathogenesis of H1N1 Influenza Virus and Swine Streptococcus suis Serotype 2 Co-Infection in Pigs by Microarray Analysis. PLoS One (2015) 0.76
Concerted action of IFN-α and IFN-λ induces local NK cell immunity and halts cancer growth. Oncotarget (2016) 0.76
Natural killer cells in hepatitis C: Current progress. World J Gastroenterol (2016) 0.76
NKp30(+) NK cells are associated with HBV control during pegylated-interferon-alpha-2b therapy of chronic hepatitis B. Sci Rep (2016) 0.75
Type III Interferons in Hepatitis C Virus Infection. Front Immunol (2016) 0.75
Interferon- α -Induced Changes to Natural Killer Cells Are Associated with the Treatment Outcomes in Patients with HCV Infections. Hepat Res Treat (2013) 0.75
NK cells and virus-related cancers. Crit Rev Oncog (2014) 0.75
IFN-λ3 polymorphism indirectly influences NK cell phenotype and function during acute HCV infection. Immun Inflamm Dis (2016) 0.75
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med (2006) 8.37
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology (2010) 7.86
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology (2006) 4.90
Projecting future complications of chronic hepatitis C in the United States. Liver Transpl (2003) 3.84
IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology (2010) 3.57
IL28B and the control of hepatitis C virus infection. Gastroenterology (2010) 3.02
Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology (2010) 2.83
Alpha and beta chemokines induce NK cell migration and enhance NK-mediated cytolysis. J Immunol (1995) 2.52
Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. J Virol (2007) 2.45
Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology (2010) 1.85
Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man. J Exp Med (2005) 1.69
Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology (2010) 1.61
Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection. Proc Natl Acad Sci U S A (2011) 1.60
Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection. Gastroenterology (2009) 1.58
Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology (2011) 1.53
Ribavirin improves early responses to peginterferon through improved interferon signaling. Gastroenterology (2010) 1.43
Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol (2007) 1.38
Interferon gamma-inducible protein 10: a predictive marker of successful treatment response in hepatitis C virus/HIV-coinfected patients. J Acquir Immune Defic Syndr (2007) 1.30
Natural killer cells: primary target for hepatitis C virus immune evasion strategies? Liver Transpl (2006) 1.29
Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment. J Immunol (2009) 1.24
Natural killer cells and hepatitis C: action and reaction. Gut (2010) 1.15
Altered interferon-alpha-signaling in natural killer cells from patients with chronic hepatitis C virus infection. J Hepatol (2010) 1.15
Matched sizes of activating and inhibitory receptor/ligand pairs are required for optimal signal integration by human natural killer cells. PLoS One (2010) 1.01
Racial differences in response to interferon-based antiviral therapy for hepatitis C virus infection: a hardwiring issue? J Infect Dis (2009) 0.81
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet (2012) 6.93
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology (2006) 4.90
Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J Virol (2009) 3.90
Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J Virol (2007) 3.83
IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology (2010) 3.57
Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology (2007) 3.57
Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology (2004) 3.47
Rare birds in North America: acute hepatitis C cohorts. Gastroenterology (2008) 3.45
An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology (2004) 3.18
Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin Invest (2010) 3.15
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology (2008) 3.14
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med (2015) 3.13
Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. J Hepatol (2011) 2.84
Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection. J Infect Dis (2009) 2.53
Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis (2007) 2.16
Levels of alanine aminotransferase confound use of transient elastography to diagnose fibrosis in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol (2012) 2.02
Liver fibrosis: insights into migration of hepatic stellate cells in response to extracellular matrix and growth factors. Gastroenterology (2003) 1.97
Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology (2011) 1.94
Immune evasion versus recovery after acute hepatitis C virus infection from a shared source. J Exp Med (2005) 1.93
Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 1.82
Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence. Hepatology (2006) 1.78
The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol (2009) 1.77
Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. Gastroenterology (2010) 1.67
Assessment of FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patients. Am J Med (2007) 1.66
Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology (2006) 1.63
A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection. PLoS One (2010) 1.62
Differential gene induction by type I and type II interferons and their combination. J Interferon Cytokine Res (2006) 1.61
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J Hepatol (2011) 1.59
Cutting edge: programmed death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: race-dependent differences. J Immunol (2008) 1.57
High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase. Hepatology (2013) 1.56
Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology (2011) 1.53
Spontaneous recovery in acute human hepatitis C virus infection: functional T-cell thresholds and relative importance of CD4 help. J Virol (2007) 1.50
Stage of cirrhosis predicts the risk of liver-related death in patients with low Model for End-Stage Liver Disease scores and cirrhosis awaiting liver transplantation. Liver Transpl (2014) 1.48
A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology (2013) 1.46
Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response. J Clin Invest (2009) 1.46
Duration of antiviral therapy for cholestatic HCV recurrence may need to be indefinite. Liver Transpl (2003) 1.44
Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response. Hepatology (2012) 1.43
Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy. Hepatology (2007) 1.42
Mechanism of T cell tolerance induction by murine hepatic Kupffer cells. Hepatology (2008) 1.41
Race- and gender-related variation in natural killer p46 expression associated with differential anti-hepatitis C virus immunity. Hepatology (2012) 1.41
Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology (2007) 1.40
A novel unsupervised method to identify genes important in the anti-viral response: application to interferon/ribavirin in hepatitis C patients. PLoS One (2007) 1.39
Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol (2007) 1.38
Myeloid suppressor cells induced by hepatitis C virus suppress T-cell responses through the production of reactive oxygen species. Hepatology (2012) 1.36
Direct enumeration and functional assessment of circulating dendritic cells in patients with liver disease. Hepatology (2004) 1.36
Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro. Hepatology (2010) 1.33
Comparison of transient elastography, serum markers and clinical signs for the diagnosis of compensated cirrhosis. J Gastroenterol Hepatol (2010) 1.33
Racial differences in liver inflammation and fibrosis related to chronic hepatitis C. Clin Gastroenterol Hepatol (2004) 1.32
Differential antigenic hierarchy associated with spontaneous recovery from hepatitis C virus infection: implications for vaccine design. J Infect Dis (2006) 1.31
Novel CD4+ and CD8+ T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection. Hepatology (2003) 1.30
Natural killer cells: primary target for hepatitis C virus immune evasion strategies? Liver Transpl (2006) 1.29
Integrin alpha1beta1 and alpha2beta1 are the key regulators of hepatocarcinoma cell invasion across the fibrotic matrix microenvironment. Cancer Res (2003) 1.29
Functional suppression by FoxP3+CD4+CD25(high) regulatory T cells during acute hepatitis C virus infection. J Infect Dis (2008) 1.29
Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus. J Infect Dis (2010) 1.28
Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology (2007) 1.27
Hepatic CD1d expression in hepatitis C virus infection and recognition by resident proinflammatory CD1d-reactive T cells. J Immunol (2004) 1.27
Risk factors for primary hepatocellular carcinoma in black and white Americans in 2000. Clin Gastroenterol Hepatol (2006) 1.25
A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection. Proc Natl Acad Sci U S A (2007) 1.24
Mechanisms of Disease: HCV-induced liver injury. Nat Clin Pract Gastroenterol Hepatol (2007) 1.22
Comprehensive assessment of chemokine expression profiles by flow cytometry. J Clin Invest (2010) 1.21
Comparison of HCV-specific intrahepatic CD4+ T cells in HIV/HCV versus HCV. Hepatology (2004) 1.19
Role of neutrophils in a mouse model of halothane-induced liver injury. Hepatology (2006) 1.19
Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C. J Hepatol (2008) 1.17
Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study. Am J Gastroenterol (2009) 1.16
Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology (2010) 1.13
Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. J Biol Chem (2013) 1.13
The blood transcriptional signature of chronic hepatitis C virus is consistent with an ongoing interferon-mediated antiviral response. J Interferon Cytokine Res (2012) 1.12
Emerging concepts in immunity to hepatitis C virus infection. J Clin Invest (2013) 1.12
Prospective analysis of effector and regulatory CD4+ T cells in chronic HCV patients undergoing combination antiviral therapy. J Hepatol (2008) 1.11
Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. Hepatology (2011) 1.10
Phenotypic and functional changes of cytotoxic CD56pos natural T cells determine outcome of acute hepatitis C virus infection. J Virol (2007) 1.08
Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C. Neurosci Lett (2004) 1.07
A general method for nested RT-PCR amplification and sequencing the complete HCV genotype 1 open reading frame. Virol J (2005) 1.06
Prostaglandin I(2) and E(2) mediate the protective effects of cyclooxygenase-2 in a mouse model of immune-mediated liver injury. Hepatology (2007) 1.05
Assessing the validity of self-reported medication adherence in hepatitis C treatment. Ann Pharmacother (2007) 1.04
Adverse outcomes in Alaska natives who recovered from or have chronic hepatitis C infection. Gastroenterology (2009) 1.04
Model-based identification of cis-acting elements from microarray data. Genomics (2006) 1.03
Hepatitis C virus diversity and evolution in the full open-reading frame during antiviral therapy. PLoS One (2008) 1.02
Interferon-stimulated gene expression in black and white hepatitis C patients during peginterferon alfa-2a combination therapy. Clin Gastroenterol Hepatol (2005) 1.02
Interleukin (IL)-17/IL-22-producing T cells enriched within the liver of patients with chronic hepatitis C viral (HCV) infection. Dig Dis Sci (2011) 1.02
The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection. Dig Dis Sci (2012) 1.01
Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection. Clin Gastroenterol Hepatol (2008) 1.00
Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection. Dig Dis Sci (2002) 0.99